OC

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Patient, OC, Neutropenia, AACR, KRON, Safety, SAN, NSCLC, Neoplasm, Cancer, MYC, ASCO, Non-Hodgkin lymphoma, Society, Therapy

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2 study, KB-0742-1001, a first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma, in a poster session at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Key Points: 
  • In addition, MYC reductions were observed in paired biopsy tumor tissues.
  • This data provides us with confidence that the 80mg four-days-on, three-days-off dose and schedule will show increased patient benefit.
  • Patients enrolled in the study had received a median of three prior treatments (range: 0-9).
  • Patients remained on treatment for an average of >2 cycles and a maximum of 14 completed cycles.

Owens Corning Announces Early Settlement Date for Exchange Offer and Consent Solicitation

Retrieved on: 
月曜日, 5月 20, 2024
Professional Services, Engineering, Other Construction & Property, Manufacturing, Finance, Construction & Property, Other Manufacturing, Exchange, Consent, Statement, Debt-to-GDP ratio, OC, Exchange offer, Date, Settlement, Participation, Computershare, Owens Corning, Wells Fargo, Masonite International, Security (finance)

Owens Corning (NYSE: OC) today announced that, in connection with the previously announced exchange offer (the “Exchange Offer”) by Owens Corning and consent solicitation (the “Consent Solicitation”) by Masonite International Corporation (“Masonite”), it has elected to have an Early Settlement Date of May 22, 2024 (the “Early Settlement Date”).

Key Points: 
  • Owens Corning (NYSE: OC) today announced that, in connection with the previously announced exchange offer (the “Exchange Offer”) by Owens Corning and consent solicitation (the “Consent Solicitation”) by Masonite International Corporation (“Masonite”), it has elected to have an Early Settlement Date of May 22, 2024 (the “Early Settlement Date”).
  • Owens Corning and Masonite are making the Exchange Offer and Consent Solicitation pursuant to the terms of and subject to the conditions set forth in the offering memorandum and consent solicitation statement dated May 1, 2024 (as amended, the “Statement”).
  • Notwithstanding the Early Settlement Date, Eligible Holders (as defined below) who did not tender at or prior to the Early Participation Deadline may still tender Existing Masonite Notes in the Exchange Offer until 5:00 p.m., New York City time, on May 30, 2024, unless such date is extended or the Exchange Offer and Consent Solicitation are earlier terminated (such date and time, as the same may be extended, the “Expiration Time”).
  • Owens Corning has engaged Morgan Stanley & Co. LLC as Lead Dealer Manager and Solicitation Agent and Wells Fargo Securities, LLC as Co-Dealer Manager and Solicitation Agent for the Exchange Offer.

Owens Corning Completes Acquisition of Masonite, Strengthening Leadership in Building and Construction Materials

Retrieved on: 
水曜日, 5月 15, 2024
Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Textiles, Engineering, Other Construction & Property, Manufacturing, Residential Building & Real Estate, Business administration, Chair, Building material, Business, OC, Special, General Mills, KitchenAid, Northwestern, Whirlpool Corporation, Owens Corning, Acquisition, Masonite International, Management

All outstanding Masonite common shares have been acquired by Owens Corning for $133.00 per share, with an implied transaction value of approximately $3.9 billion.

Key Points: 
  • All outstanding Masonite common shares have been acquired by Owens Corning for $133.00 per share, with an implied transaction value of approximately $3.9 billion.
  • “The addition of Masonite to Owens Corning marks a significant milestone for our company, as we further strengthen our position as a market leader in building and construction materials,” said Brian Chambers, Chair and Chief Executive Officer of Owens Corning.
  • “Over the past several years, Owens Corning has been on a journey to transform and grow our company through strategic choices and strong execution.
  • The acquisition drives meaningful shareholder value creation with ROIC exceeding Owens Corning’s cost of capital by the end of Year 3 post-close.

Owens Corning and Masonite Announce the Extension of the Expiration Time and Early Participation Deadline for Tender Offer and Consent Solicitation

Retrieved on: 
火曜日, 5月 14, 2024
Other Construction & Property, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Textiles, Consent, Building material, OC, Expiration, Solicitation, News, Participation, Tender offer, Acquisition, Arrangement, Masonite International, Owens Corning, Property management

All other terms of the Tender Offer and Consent Solicitation remain as set forth in the Statement (as defined below).

Key Points: 
  • All other terms of the Tender Offer and Consent Solicitation remain as set forth in the Statement (as defined below).
  • The settlement date for the Tender Offer and Consent Solicitation will be promptly after the Expiration Time.
  • Owens Corning and Masonite reserve the right to terminate, withdraw, amend or extend the Tender Offer and Consent Solicitation, including to extend the Expiration Time without extending the Early Participation Deadline, as described in the Statement.
  • The deadline to withdraw Masonite Notes and revoke related consents tendered and delivered in the Tender Offer and Consent Solicitation was 5:00 p.m., New York City time, on April 26, 2024, which deadline has not been extended.

Endless Summer Events Took Salt Creek Beach by Storm with 2024 Dana Point Film Festival

Retrieved on: 
月曜日, 5月 6, 2024
Entertainment, Film & Motion Pictures, Music, Events, Concerts, Dana Point, California, Common Sense, Wave, Endless, VIP, The Endless Summer, White, Ministry, Into, Step into Liquid, Multimedia, Athlete, OC, Endless Summer, Darkness, CPR, Film industry

The Endless Summer + Dana Point Film Festival saw record breaking attendance of approximately 5,000 at its second annual event May 2-5.

Key Points: 
  • The Endless Summer + Dana Point Film Festival saw record breaking attendance of approximately 5,000 at its second annual event May 2-5.
  • View the full release here: https://www.businesswire.com/news/home/20240506595336/en/
    Pictured: Tony Cordova and Alex Mecl, co-founders and CEOs, and Lloyd Bryan Molander, founder and festivals director of the Endless Summer + Dana Point Film Festival, with Dick Metz, the inspiration behind the Endless Summer movie, and Dana Brown, director of Step Into Liquid.
  • The day concluded with a vibrant beach party at Salt Creek Beach, where surf reggae band Common Sense performed, followed by a screening of Dana Brown’s classic film, “Step Into Liquid.” The events offered engaging experiences for all ages.
  • The Dana Point Film Festival team was thrilled with the turnout and support for ocean conservation.

Breaking Barriers: Maryland RV Law Changes Revolutionizes OC RV & Van Lifestyle Show

Retrieved on: 
火曜日, 5月 7, 2024
Recreational vehicle, Big-box store, Growth, Lippert, Golf, Legislation, OC, Self storage

, May 7, 2024 /PRNewswire/ -- The OC RV & Van Lifestyle Show, scheduled for October 31 to November 3, 2024, at the Roland E. Powell Convention Center, is gearing up for an unprecedented expansion driven by transformative Maryland RV legislation.

Key Points: 
  • , May 7, 2024 /PRNewswire/ -- The OC RV & Van Lifestyle Show, scheduled for October 31 to November 3, 2024, at the Roland E. Powell Convention Center, is gearing up for an unprecedented expansion driven by transformative Maryland RV legislation.
  • The passage of Bill SB-60 has opened the doors wide for the first time in decades, allowing out-of-state RV dealers to display at Maryland RV shows.
  • Together, these legislative changes are set to redefine the RV marketplace in Maryland, offering both in and out-of-state dealers opportunities for growth and customer engagement at the OC RV & Van Lifestyle Show.
  • Its scenic beaches, ample amenities, and welcoming community make it the ideal setting for the OC RV & Van Lifestyle Show .

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
土曜日, 5月 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

Hoag Empowers Hundreds of Employees to Participate in the Hoag OC Marathon

Retrieved on: 
木曜日, 5月 2, 2024
Last, Health, Wellness, Partnership, Orange County Fair, Nursing, Physician, OC, Running, Medicine

NEWPORT BEACH, Calif., May 2, 2024 /PRNewswire/ -- Team Hoag is coming out strong with more than 300 employees ready to participate in the Hoag OC Marathon Running Festival taking place May 3-5, 2024.

Key Points: 
  • In Hoag's first year as title sponsor, more than 300 Hoag employees will participate in the Hoag OC Marathon running events May 3-5, 2024
    NEWPORT BEACH, Calif., May 2, 2024 /PRNewswire/ -- Team Hoag is coming out strong with more than 300 employees ready to participate in the Hoag OC Marathon Running Festival taking place May 3-5, 2024.
  • Our sponsorship of events like the Hoag OC Marathon aligns perfectly with our mission to promote holistic health and well-being."
  • The Hoag OC Marathon will kick off with a two-day Health and Fitness Expo at the OC Fair & Event Center on May 3rd and May 4th.
  • For more information about the Hoag OC Marathon or to register, please visit ocmarathon.com.

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

Retrieved on: 
木曜日, 4月 25, 2024
Phases of clinical research, Paclitaxel, Cell, Safety, Pharmacokinetics, Drug development, PP2A, Apoptosis, Index, Conference, PDAC, MTD, Patient, Principal, OC, AACR, Curie Institute (Paris), Pharmaceutical industry

PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.

Key Points: 
  • PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.
  • Four sites in France are currently recruiting: Institut Curie, Gustave Roussy, Centre François Baclesse and Institut de Cancérologie de l'Ouest.
  • “We are thrilled to see the first patients dosed in this Phase Ib trial.
  • Christophe Le Tourneau, Medical Oncologist at Institut Curie, Head of the Department of Drug Development and Innovation (D3i), and Principal Investigator of the CLEVer-PEPtide trial.

Sun European Partners, LLP Affiliate Agrees to Sell Adler & Allan to Goldman Sachs Alternatives

Retrieved on: 
火曜日, 4月 30, 2024
Other Professional Services, Sustainability, Environment, Finance, Consulting, Banking, Professional Services, Green Technology, Goldman Sachs, Sale, Climate change, Professionalization, Water, LLP, KPMG, Partner, Sun, Commercial, GS, Partnership, Weil, Gotshal & Manges, Private equity, Hydrocarbon, Legislation, Acquisition, Food, Energy, Pleasure, OC, Houlihan Lokey, Linklaters, Growth, Ecosystem, Security (finance)

An affiliate of Sun European Partners, LLP (“Sun European Partners” or “Sun European”), today announces that it has agreed to sell Adler & Allan (or the “Company”) a leading UK environmental risk reduction specialist to the private equity business at Goldman Sachs Alternatives (or “Goldman Sachs”).

Key Points: 
  • An affiliate of Sun European Partners, LLP (“Sun European Partners” or “Sun European”), today announces that it has agreed to sell Adler & Allan (or the “Company”) a leading UK environmental risk reduction specialist to the private equity business at Goldman Sachs Alternatives (or “Goldman Sachs”).
  • Adler & Allan was acquired by an affiliate of Sun European in November 2020.
  • Alexander Wyndham, Managing Director at Sun European Partners, said: “It was a pleasure working alongside Bob, Henrik, and the whole Adler & Allan team.
  • We look forward to our partnership with the Goldman Sachs team and a new growth phase for Adler & Allan.